 Heidelberg, Germany, November 4, 2020 Affimed N.V., NASDAQ: AFMD a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, announced today that two abstracts highlighting data related to the companys lead innate cell engager ICE, AFM13, have been accepted for poster presentation at the virtual 62nd American Society of Hematology ASH Annual Meeting and Exposition being held December 5-8, 2020. 